Cytokeratins are structural proteins forming the subunits of epithelial intermediary filaments. Fragments of cytokeratin-19 (CYFRA 21-1) are frequently released into the blood of cancer patients. Due to the high specificity relative to benign lung diseases,it is suitable for use as a differentiation marker in tumor pathology especially in lung cancer.

Bovine Cytokeratin fragment antigen 21-1 (CYFRA21-1) ELISA Kit employs a two-site sandwich ELISA to quantitate CYFRA21-1 in samples. An antibody specific for CYFRA21-1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyCYFRA21-1 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for CYFRA21-1 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of CYFRA21-1 bound in the initial step. The color development is stopped and the intensity of the color is measured.

Bovine Cytokeratin fragment antigen 21-1 (CYFRA21-1) ELISA Kit listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.